Antibiotic chemotherapy of bacterial sexually transmitted diseases in adults: a review.
Treatment regimens for sexually transmitted infections continue to evolve. The natural history of syphilis in HIV-infected patients is leading to more aggressive policies in terms of both investigation and treatment. In particular, treatment protocols for late syphilis, especially neurosyphilis, are under scrutiny. Epidemiological change typified by the spread of penicillinase-producing Neisseria gonorrhoeae (PPNG) has led to a search for new agents to treat gonorrhoea, with a more extensive use of cephalosporin and quinolone antibiotics emerging. The problem of compliance with the antibiotic courses presently required for chlamydial infection may be close to being solved with the development of newer macrolide agents. Single dose azithromycin, although expensive, seems to be as effective as longer courses with other agents. Furthermore, its efficacy in gonococcal infection is also encouraging. Increased understanding of the pathogenesis and natural history of pelvic inflammatory disease (PID) and bacterial vaginosis (BV) has led to rationalization of treatment policies for these conditions.
Corcoran
G D
GD
Department of Clinical Microbiology, University College London Hospitals, UK.
Ridgway
G L
GL
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy; D015658:HIV Infections / Q000150:complications; D006801:Humans; D008297:Male; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D015231:Sexually Transmitted Diseases, Bacterial / Q000188:drug therapy*; D013587:Syphilis / Q000150:complications / Q000188:drug therapy; D014526:Urethritis / Q000188:drug therapy; D016585:Vaginosis, Bacterial / Q000188:drug therapy
D000900:Anti-Bacterial Agents